Last $23.35 USD
Change Today -0.185 / -0.79%
Volume 67.2K
KITE On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 5:20 PM 07/29/14 All times are local (Market data is delayed by at least 15 minutes).

kite pharma inc (KITE) Snapshot

Open
$23.60
Previous Close
$23.53
Day High
$24.06
Day Low
$22.90
52 Week High
06/24/14 - $32.65
52 Week Low
07/16/14 - $21.00
Market Cap
886.9M
Average Volume 10 Days
221.9K
EPS TTM
--
Shares Outstanding
38.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for KITE PHARMA INC (KITE)

Related News

No related news articles were found.

kite pharma inc (KITE) Related Businessweek News

No Related Businessweek News Found

kite pharma inc (KITE) Details

Kite Pharma, Inc. operates a clinical-stage biopharmaceutical company which focuses on the development and commercialization of novel cancer immunotherapy products. The company is developing a pipeline of eACT-based product candidates for the treatment of solid and hematological malignancies. Its lead product candidate includes KTE-C19, a chimeric antigen receptors-based engineered autologous cell therapy for the treatment of patients with relapsed/refractory diffuse large B cell lymphoma. The company is also developing T cell receptors-based therapies, which targets SSX2, NY-ESO-1, and MAGE antigens in various cancers. The company has collaboration agreement with the Surgery Branch of the National Cancer Institute. Kite Pharma, Inc. was founded in 2009 and is headquartered in Santa Monica, California.

19 Employees
Last Reported Date: 06/23/14
Founded in 2009

kite pharma inc (KITE) Top Compensated Officers

Founder, Executive Chairman, Chief Executive ...
Total Annual Compensation: $16.7K
Vice President of Translation Medicine
Total Annual Compensation: $325.0K
Consultant
Total Annual Compensation: $210.9K
Compensation as of Fiscal Year 2013.

kite pharma inc (KITE) Key Developments

Kite Pharma, Inc.(NasdaqGS:KITE) added to NASDAQ Composite Index

Kite Pharma, Inc. will be added to the NASDAQ Composite Index.

Kite Pharma, Inc. Announces Executive Changes

Kite Pharma, Inc. announced the expansion of Kite's research and development leadership team with the appointments of William Y. Go, M.D., Ph.D., as Senior Director, Clinical Development and Jeff Aycock as Senior Director, Clinical Operations. Prior to joining Kite, Dr. Go held senior positions of increasing responsibility at Amgen, most recently as U.S. Medical Lead for Vectibix(R), Medical Director in Global Development. He led the US Vectibix(R) Development team to a successful label expansion of this product and also served as clinical lead for the Amgen's immunotherapy strategy team. Mr. Aycock brings more than 17 years of drug development experience investigating a broad range of oncology drug candidates in both the pediatric and adult settings. Prior to joining Kite, Mr. Aycock held roles of increasing responsibility over 13 years at Amgen.

Kite Pharma, Inc. Appoints David D. Chang as Executive Vice President, Research and Development, and Chief Medical Officer

Kite Pharma, Inc. announced the appointment of David D. Chang, M.D., Ph.D., as Executive Vice President, Research and Development, and Chief Medical Officer. Dr. Chang brings a substantial track record of innovation within oncology drug development, having most recently served as Vice President of Global Development and Head of Hematology-Oncology at Amgen. His appointment at Kite is effective immediately. Prior to joining Kite, Dr. Chang held leadership roles of increasing responsibility during his more than decade-long tenure at Amgen. As Vice President of Global Development and Head of Hematology-Oncology, he spearheaded personalized therapy strategies underlying the success of colon cancer drug Vectibix(R).

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KITE:US $23.35 USD -0.185

KITE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for KITE.
View Industry Companies
 

Industry Analysis

KITE

Industry Average

Valuation KITE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 6.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KITE PHARMA INC, please visit www.kitepharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.